This module is designed to support pharmacists and other healthcare professionals to understand the new guidance and requirements around the safe supply of Valproate medicines.
- Understand the background to the new regulations around the supply of valproate medicines.
- Learn about the risks around the supply of valproate medicines to girls and women.
- Find out about the latest advice concerning the supply of valproate to women an girls.
- Be signposted to further educational resources available to support the safe supply of valproate.
As with any medicine related issue pharmacists have a key role to play. Janice Perkins FRPharmS, Chair of the Community Pharmacy Patient Safety Group commented:
“Community pharmacy teams are perfectly placed to support women and girls taking valproate, working closely with their local GP surgery teams to raise awareness, reduce potential risks of harm and make a difference.”
None of the content here may be reproduced. The rights to the content sit with GenX media Ltd. In any medical field, information is updated over time. Procedures and practices, therefore, will inevitably change too. The authors and reviewers have made every effort to make sure information within these modules is both up to date at the time of publication and accurate also. It is the responsibility of the healthcare professional to make informed professional decisions. The information should also be used in the context of local guidance. GenX media Ltd. can take no responsibility for any prescribing errors that may happen. Where drug dosing is concerned we advise readers to consult the BNF or the summary of product characteristics for the particular drug.
References and acknowledgements
The content of this module is based on the following reference sources.
1. Medicines healthcare regulatory authority: Valproate use by women and girls available here. (accessed 1/8/18)
2. Community pharmacy patient safety group website available here. (accessed 1/8/18)